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For over half a century, warfarin or other vitamin 
K antagonists (VKA) (such as acenocoumarol, 
available in Greece and other countries), have been the 
gold standard and the only oral anticoagulants available 
which have been shown to effectively treat 
thromboembolism.1-3 However, their use has been 
plagued by inherent limitations with cumbersome 
monitoring via laboratory-guided adjustments of the 
dose, narrow therapeutic window, a lot of drug and 
food interactions and unpredictable and variable 
response.  This has hindered patient compliance and has 
led to suboptimal therapy and poor anticoagulation 
control. Also patients unable or unwilling to take VKA 
have been offered no other choice of equivalent 
efficacy, i.e. until recently. Reasons for not receiving a 
VKA may comprise the following: drug allergy, patient 
refusal to take or decision to discontinue the drug, 
inability to maintain the international normalized ratio 
(INR) in the 2.0-3.0 range, physician decision as to the 
inappropriateness of receiving the drug, and/or inability 
to monitor the INR (lack of or difficulty in accessing a 
laboratory or lack of family support or assistance with 
this tedious task).  
These hurdles of conventional anticoagulant 
therapy have spawned efforts to develop new 
medications that will surpass these drawbacks while 
matching the efficacy of VKAs.3-8 Factor Xa has a 
strategic role in the coagulation cascade, critically 
poised at the juncture of the contact activation 
(intrinsic) and the tissue factor (extrinsic) coagulation 
pathways proximal to thrombin, both activating the 
final common pathway and leading to fibrin formation. 
Active factor Xa hydrolyzes and activates prothrombin 
to thrombin. Thrombin is the most important 
constituent of the coagulation cascade and has a broad 
array of functions with a primary role in the conversion 
of fibrinogen to fibrin, the building structure of a 
hemostatic plug. Significant advances have been 
accomplished in the development of more specific 
agents targeting coagulation factors II (thrombin) or Xa 
and providing more predictable and stable 
anticoagulant responses by not interfering with diet, 
and having fewer interactions with other drugs. They 
also provide the convenience of oral administration 
with fixed dose regimens not necessitating routine 
monitoring with laboratory tests, all these having a 
positive impact on patient compliance. Novel oral 
agents like the thrombin inhibitor dabigatran etexilate 
and the factor Xa inhibitor rivaroxaban, have already 
become available for prevention of deep venous 
thromboembolism after orthopedic procedures, such as 
elective hip and knee arthroplasty, while other factor 
Xa inhibitors (apixaban and edoxaban) are being 
evaluated in phase III clinical trials. The initial results 
of the studies employing these new compounds are 
promising and provide evidence of improvement in 
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treatment of venous thromboembolism and in the 
prevention of stroke in patients with non-valvular atrial 
fibrillation. 
 The RE-LY trial has recently demonstrated that the 
oral direct thrombin inhibitor, dabigatran etexilate, is an 
effective alternative for oral anticoagulation with VKAs 
for stroke prevention in patients with atrial 
fibrillation.3,4 After initial failures with similar 
medications (e.g. ximelagatran, charged with liver 
dysfunction), these results constitute a breakthrough in 
anticoagulation therapy. In the RE-LY trial, in patients 
with atrial fibrillation and at least one additional risk 
factor for stroke, dabigatran 150 mg bid reduced both 
stroke and intracranial and life-threatening hemorrhage 
without any significant increase in overall major 
hemorrhages compared with warfarin, whereas the 
lower dose of dabigatran (110 mg bid) while non-
inferior at reducing risk of stroke, it reduced 
intracranial, life-threatening, and major bleeding. 
Dyspepsia was a more frequent side-effect of 
dabigatran (11-12%) compared with warfarin (~6%). 
Importantly, dabigatran did not cause hepatotoxicity. 
However, a word of caution relates to the occurrence of 
bleeding while receiving dabigatran, as there is no 
specific antidote for this drug, which has a half-life of 
12-17 hours. Supportive therapy for severe bleeding 
may include transfusions of fresh-frozen plasma, 
packed red blood cells, or exploratory surgery if 
indicated. 
 The American Food & Drug Administration 
(FDA) approved dabigatran on October 19, 2010 for 
anticoagulant use in patients with nonvalvular atrial 
fibrillation.5 However, only the higher dose (150 mg 
bid) was approved for patients with a creatinine 
clearance >30 mL/min. In patients with severe renal 
insufficiency (creatinine clearance 15 to 30 mL/min) 
half the dose (75 mg bid) was recommended, which 
however was not evaluated in the RE-LY trial. 
Dabigatran has also been approved in Canada and at 
least 12 other countries and awaits approval by the 
European Medicines Agency (EMA). Dabigatran 
(Pradaxa®, Boehringer Ingelheim) is the first new oral 
anticoagulant to become available for clinical use in 
over half a century.  
 Other novel oral anticoagulant agents next in line 
to receive approval for marketing for stroke prevention 
in patients with atrial fibrillation include the factor X 
inhibitors, rivaroxaban (Xarelto®, Bayer/Johnson & 
Johnson) which is an oxazolidinone derivative assessed 
in the ROCKET-AF trial and found to be non-inferior 
to warfarin,7 apixaban (Eliquis®, Pfizer / Bristol-Myers 
Squibb) evaluated in the AVERROES trial but only 
versus aspirin,6 while its comparison with warfarin in 
the ARISTOTLE trial is still pending,8 and edoxaban 
(Lixiana®, Daiichi Sankyo) which is being compared 
with warfarin in the ENGAGE AF TIMI-48 trial.8 The 
shorter half-life of these new agents will probably 
improve their safety profile, but, on the other hand, it 
will also pose a risk of inferior protection if doses are 
missed. These new drugs are substrates for P-
glycoprotein and they are metabolized by cytochrome 
P-450 3A4.8 Hence, caution is advised to avoid the 
concomitant use of drugs that inhibit these pathways, 
such as azole antifungal agents or protease inhibitors. 
Finally, the cost issue is very important, as the cost of 
these new agents will be much higher than that of 
VKAs, and needs to be factored into the decision-
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